Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 489,300 | 206,600 | 583,600 | 586,400 | 416,300 |
| Depreciation Amortization | 38,300 | 19,100 | 81,900 | 60,700 | 40,000 |
| Income taxes - deferred | 18,900 | -15,500 | 17,800 | 44,100 | 43,700 |
| Accounts receivable | 2,600 | 27,400 | -27,800 | -20,700 | -74,800 |
| Other Working Capital | -309,300 | -82,100 | 240,900 | -123,700 | -238,700 |
| Other Operating Activity | 51,700 | -4,200 | 104,300 | 90,000 | 139,500 |
| Operating Cash Flow | $291,500 | $151,300 | $1,000,700 | $636,800 | $326,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | -3,100 | N/A | N/A | -5,800 |
| PPE Investments | -96,000 | -43,200 | -168,100 | -116,200 | -73,900 |
| Net Acquisitions | N/A | N/A | -192,900 | -84,900 | -84,800 |
| Purchase Of Investment | 0 | -1,800 | -1,334,700 | -1,194,700 | -837,600 |
| Sale Of Investment | 440,600 | 280,800 | 1,103,400 | 714,000 | 521,400 |
| Purchase Sale Intangibles | -3,000 | -3,000 | -7,400 | N/A | -6,400 |
| Other Investing Activity | -19,400 | -12,400 | -54,900 | -14,700 | -6,300 |
| Investing Cash Flow | $325,200 | $220,300 | $-647,200 | $-696,500 | $-487,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 5,100 | N/A | 989,300 | N/A |
| Debt Issued | 685,800 | N/A | 994,700 | N/A | 985,400 |
| Debt Repayment | -522,200 | -5,100 | -818,400 | -812,800 | -808,200 |
| Common Stock Issued | 84,300 | 44,800 | 113,800 | 91,300 | 68,700 |
| Common Stock Repurchased | -350,400 | -2,100 | -763,300 | -512,000 | -511,200 |
| Other Financing Activity | -97,300 | -1,800 | 0 | 0 | 800 |
| Financing Cash Flow | $-199,800 | $40,900 | $-473,200 | $-244,200 | $-264,500 |
| Exchange Rate Effect | -8,800 | -3,800 | 7,900 | 4,100 | 3,600 |
| Beginning Cash Position | 818,300 | 818,300 | 930,100 | 930,100 | 930,100 |
| End Cash Position | 1,226,400 | 1,227,000 | 818,300 | 630,300 | 508,200 |
| Net Cash Flow | $408,100 | $408,700 | $-111,800 | $-299,800 | $-421,900 |
| Free Cash Flow | |||||
| Operating Cash Flow | 291,500 | 151,300 | 1,000,700 | 636,800 | 326,000 |
| Capital Expenditure | -96,000 | -43,200 | -168,100 | -116,200 | -73,900 |
| Free Cash Flow | 195,500 | 108,100 | 832,600 | 520,600 | 252,100 |